5-bromo-2,7-naphthyridin-1(2H)-one | 1260663-94-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-bromo-2,7-naphthyridin-1(2H)-one
• 英文别名: 5-bromo-2H-2,7-naphthyridin-1-one
• CAS: 1260663-94-2
• 化学式: C₈H₅BrN₂O
• 分子量: 225.044
• InChiKey: NABGQOLVZFQDJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-2,7-naphthyridin-1(2H)-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydride 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 5-benzylsulfanyl-2-methyl-2.7-naphthyridin-1-one
  参考文献：
  名称：

  [EN] NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS DE SULFONAMIDE D'ISOQUINOLINONE, DE PYRROLOPYRIDINONE ET DE THIÉNOPYRIDINONE

  摘要：

  The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3and W are as described herein, composition including the compounds and methods of using the compounds.

  公开号：

  WO2024017856A1

文献信息

• [EN] BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES BICYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2023209088A1

  公开（公告）日：2023-11-02

  The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cancer.

  本说明书涉及式（I）化合物：(I) 及其药学上可接受的盐、用于制备它们的工艺和中间体、含有它们的药物组合物以及它们在治疗癌症中的用途。
• INHIBITORY COMPOUNDS
  申请人：[en]STORM THERAPEUTICS LIMITED

  公开号：WO2024126987A1

  公开（公告）日：2024-06-20

  The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity, wherein Formula (I) is as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, disorders of the central nervous system and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
• [EN] 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS 6,6 EN TANT QU'INHIBITEURS DE METTL3
  申请人：[en]858 THERAPEUTICS, INC.

  公开号：WO2023129933A2

  公开（公告）日：2023-07-06

  The present disclosure relates to 6,6-fused heterocyclic compounds and related compounds and their use in treating a disease or condition responsive to modulation or inhibition of METTL3.